







Atlas Genet Cytogenet Oncol Haematol. 2013; 17(1)  28 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
MED28 (mediator complex subunit 28) 
Ming-Fen Lee, Chun-Yin Huang 
Department of Nutrition and Health Sciences, Chang Jung Christian University, 396 Sec 1 Changrong Rd, 
Gueiren Dist, Tainan, Taiwan 71101, China (MFL), Department of Nutrition, China Medical University, 91 
Hsueh-Shih Road, Taichung, Taiwan 40402, China (CYH) 
 
Published in Atlas Database: July 2012 
Online updated version : http://AtlasGeneticsOncology.org/Genes/MED28ID50131ch4p15.html 
DOI: 10.4267/2042/48468 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2013 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: 1500003D12Rik, EG1, magicin 




MED28 mRNA is identical to AF317679, AF358829, 
and AF321617 with the respective size of ~1, ~1.3, and 
~3.2 kb (Wiederhold et al., 2004). They vary in the 
untranslated region, but share the same protein product. 
Protein 
Description 
The full-length MED28 protein consists of 178 amino 
acids with a predicted molecular weight ~20 kDa 
(Wiederhold et al., 2004). MED28, an evolutionaly 
conserved protein, was identified as an endothelial-
derived gene, EG-1 (Liu et al., 2002).  
MED28 was also identified as a merlin-interacting 
protein by yeast two-hybrid screen (Wiederhold et al., 
2004), where merlin, the neurofibromatosis 2 (NF2) 
tumor suppressor protein, belongs to the ezrin-radixin-
moesin (ERM) family members. Affinity-binding 
assays demonstrated that MED28 interacted with the 
SH3 domains of Grb2 (Wiederhold et al., 2004).  
Accordingly, MED28 was also named as magicin, 
merlin and Grb2 interacting cytoskeletal protein 
(Wiederhold et al., 2004).  
In addition, several Src family members, including Src, 
Fyn, and Lck, are also MED28-associated partners (Lee 
et al., 2006; Lu et al., 2006). Therefore, 
MED28/magicin/EG-1 may function as an 
adaptor/scaffold to relay cellular signaling (Lee et al., 
2006).  
Furthermore, MED28 is also found in the nucleus 
where it is presumably involved in gene transcription as 
part of the Mediator complex (Sato et al., 2004). It is 
likely that MED28 shuttles between nucleus, 
cytoskeleton, and cytoplasm to convey its physiological 
role. 
 
Figure 1. Diagram of pre-mRNA of MED28. The black bars are exons. 
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Figure 2. MED28 interacting proteins. 
 
Expression 
MED28 is expressed in multiple human tissues 
(Wiederhold et al., 2004), with high expression in liver, 
placenta, and testis (Liu et al., 2002). 
MED28-interacting proteins: merlin, actin, Grb2 
(Wiederhold et al., 2004), Fyn, Lck, Src (Lee et al., 
2006; Lu et al., 2006), Mediator subunits (Sato et al., 
2004). 
Localisation 
Cytoskeleton, cytoplasm, and nucleus (Sato et al., 
2004; Wiederhold et al., 2004). 
Function 
MED28 may be involved in the regulation of numerous 
biological processes, including transcriptional 
regulation, cytoskeletal organization, signal 
transduction, cell proliferation, differentiation, 
angiogenesis, and migration (Beyer et al., 2007; Huang 
et al., 2012; Liu et al., 2002; Wiederhold et al., 2004; 
Yoon et al., 2010; Zhang et al., 2004). 
Transcription regulation: 
The Mediator complex is a set of protein coactivators 
that bridges DNA-binding transcription factors to 
transcriptional activation of the RNA polymerase II 
(pol II). MED28 was identified as a subunit of the 
mammalian Mediator complex by the multidimensional 
protein identification technology (MudPIT) (Sato et al., 
2004). This identification indicates a role of MED28 in 
the regulation of gene transcription. 
Cytoskeletal organization: 
The implication of MED28 in cytoskeletal re-
organization was based on the observation that 
MED28, similar to merlin, co-localizes with the actin 
cytoskeleton as determined by cofractionation, 
immunofluorescence and electron microscopy 
(Wiederhold et al., 2004). 
Signal transduction: 
Ectopic expression of MED28 led to increased 
phosphorylation of mitogen-activated protein kinases 
(MAPK) (Lu et al., 2005). In contrast, MED28-specific 
knockdown resulted in decreased expression of 
mitogen-activated protein kinase kinase 1 
(MAP2K1/MEK1) in MCF7 cells (Huang et al., 2012). 
In addition, overexpression of MED28 resulted in the 
activation of c-Src (Lu et al., 2006) and MED28 can be 
phosphorylated at Y64 by Fyn, a Src family member 
(Lee et al., 2006). These data indicate that MED28 may 
function as a regulator of cellular signal transduction 
pathways. 
Cell proliferation:  
Ectopic overexpression of MED28 resulted in enhanced 
cell growth in immortal human embryonic kidney 
(HEK) 293 cells, and breast cancer cell lines, MCF7 
and MDA-MB-231 (Lu et al., 2005). The HEK293 
xenograft tumor growth was also stimulated in 
MED28-overexpressing cells (Lu et al., 2005). 
Smooth muscle cell differentiation:  
MED28 functions a repressor of smooth muscle cell 
(SMC) differentiation (Beyer et al., 2007). MED28-
specific knockdown resulted in up-regulation of several 
SMC-related genes and SMC phenotype, whereas 
ectopic expression of MED28 reversed the SMC 
morphology induced by MED28 knockdown (Beyer et 
al., 2007). 
Angiogenesis: 
MED28 expression was increased by two-fold in 
human umbilical vein endothelial cells (HUVECs) 
treated with either tumor conditioned media or specific 
angiogenic factors (Liu et al., 2002). This observation 
suggests a role of MED28 in angiogenesis. 
Cell migration: 
The role of MED28 in cell migration was demonstrated 
in both estrogen receptor (ER)-positive and negative 
human breast cancer cell lines (Huang et al., 2012; Lee 
et al., 2011).  
Ectopic expression of MED28 increased cell migration 
and invasion in MCF7 and MDA-MB-231 breast 
cancer cells (Huang et al., 2012; Lee et al., 2011). 
Investigation of the underlying mechanisms revealed 
that MED28 activates epidermal growth factor (EGF)-
stimulated migration through induction of matrix 
metalloproteinase 9 (MMP9) in EGFR-overexpressing 
MDA-MB-231 cells (Lee et al., 2011).  






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(1)  30 
 
Figure 3. Biological functions of MED28. 
 
In addition, MED28 can also regulate cell migration 
through the mitogen-activated protein kinase kinase 1 
(MAP2K1; MEK1)-dependent MMP2 activation, 
which is independent of EGF stimulation (Huang et al., 
2012). These lines of evidence support the role of 
MED28 in cell migration, implying that MED28 might 
be responsible for cancer metastasis. 
Homology 
MED28 has significant homology to a mouse cDNA 
(94%), fish, and a fly cDNA (31%) (Liu et al., 2002; 
Wiederhold et al., 2004). The mouse MED28 gene is 




MED28 expression is elevated in cancers including 
breast, colorectal, and prostate cancers, suggesting a 
role of MED28 in malignant phenotype of epithelial-
derived cancers (Liu et al., 2002; Zhang et al., 2004). 
Further tissue microarray (TMA) analysis on a set of 
breast cancer population also showed elevated MED28 
expression in the ductal carcinoma in situ (DCIS) and 
invasive ductal carcinoma lesions (Yoon et al., 2010). 
Such elevated MED28 expression independently 
predicts poor survival (Yoon et al., 2010). These data 
indicate that MED28 may be a potential therapeutic 
target in cancer intervention. Indeed, MED28 
suppression via either siRNA lentivirus or polyclonal 
antibody resulted in decreased growth of both MCF7 
and MDA-MB-231 cell lines and their corresponding 
xenograft tumors in mice (Lu et al., 2007). 
Furthermore, the in vitro application of phytochemical 
resveratrol potently inhibited EGF-stimulated cell 
migration via suppression of MED28 in MDA-MB-231 
breast cancer cells (Lee et al., 2011). 
Prognosis 
The evidence supporting MED28 as a prognostic factor 
is emerging. MED28 peptide was detectable in serum 
and urine of a small set of breast cancer patients (Lu et 
al., 2007). In addition, statistical analysis on the 
correlation between MED28 and survival time or time-
to-relapse indicates that MED28 is a significant 
predictor of malignant breast cancer (Yoon et al., 
2010). 
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